SCHEMBL1655783

SCHEMBL1655783

CCOC(=O)C(CC)CCO

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 2/20 0.45
CA1 P00915 1/20 0.45
CPB2 Q96IY4 2/20 0.42
ALDH1A1 P00352 3/20 0.40
MEN1 O00255 1/20 0.39
NPC1 O15118 1/20 0.39
KMT2A Q03164 1/20 0.39
LMNA P02545 1/20 0.39
HSD17B10 Q99714 1/20 0.39
ALOX15 P16050 1/20 0.37
MGAM O43451 1/20 0.37
GAA P10253 1/20 0.37
SI P14410 1/20 0.37
MGAM2 Q2M2H8 1/20 0.37
SOAT1 P35610 1/20 0.37
MAPK1 P28482 1/20 0.35
EPHX2 P34913 2/20 0.35
PPARG P37231 2/20 0.35
CAD P27708 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20704277 1.00 CA2 (0.45) CA2CA1CPB2ALDH1A1MEN1
SCHEMBL21052387 0.88 CA2 (0.50) CA2CA1CPB2ALDH1A1MEN1
SCHEMBL1405922 0.86 CPB2 (0.42) CPB2ALDH1A1MEN1NPC1KMT2A
SCHEMBL17523695 0.84 HDAC1 (0.44) CA2CA1CPB2ALDH1A1MEN1
Acetic Acid SCHEMBL3158726 0.84 ALDH1A1 (0.42) CPB2ALDH1A1MEN1NPC1KMT2A
Acetic Acid SCHEMBL1820606 0.84 ALDH1A1 (0.42) CPB2ALDH1A1MEN1NPC1KMT2A
SCHEMBL28078262 0.84 HDAC1 (0.44) CA2CA1CPB2ALDH1A1MEN1
SCHEMBL17617131 0.84 CA2 (0.52) CA2CA1CPB2ALDH1A1MEN1
SCHEMBL9372700 0.84 CA2 (0.47) CA2CA1ALDH1A1GAASOAT1
SCHEMBL13575662 0.84 CA2 (0.52) CA2CA1CPB2ALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101433308-A O/W type food level beta-carotene microemulsion carrier and preparation method thereof UNIV SHANGHAI JIAOTONG (CN) 2009-05-20 CN claimed
EP-0423873-A2 Process for making improved citrus aqueous essence THE PROCTER & GAMBLE COMPANY (US) 1991-04-24 EP claimed
US-4970085-A FLAVORS THE PROCTER & GAMBLE COMPANY (US) 1990-11-13 US claimed
WO-2011073929-A1 6-(2-FURYL)-3-METHYL-4-OXO-1,5,6,7-TETRAHYDROINDOLE-2-CARBOXYLATE DERIVATIVES AND USES THEREOF ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) 2011-06-23 WO disclosed
WO-2011045265-A2 SPIROCYCLIC DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS DAC S.R.L. (IT) 2011-04-21 WO disclosed
CN-101433308-A O/W type food level beta-carotene microemulsion carrier and preparation method thereof UNIV SHANGHAI JIAOTONG (CN) 2009-05-20 CN disclosed
CN-101433308-A O/W type food level beta-carotene microemulsion carrier and preparation method thereof UNIV SHANGHAI JIAOTONG (CN) 2009-05-20 CN disclosed
US-6949546-B2 N-ureidoheterocycloalkyl-piperidines as modulators of chemokine receptor activity BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2005-09-27 US disclosed
US-20040058961-A1 N-ureidoheterocycloalkyl-piperidines as modulators of chemokine receptor activity KO SOO S (US) 2004-03-25 US disclosed
US-6627629-B2 Useful for the treatment or prevention of asthma and other allergic diseases. BRISTOL-MYERS SQUIBB PHARMA 2003-09-30 US disclosed
EP-1296978-A2 N-UREIDOHETEROCYCLOAKLYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY BRISTOL-MYERS SQUIBB COMPANY (US) 2003-04-02 EP disclosed
US-20030032654-A1 N-ureidoheterocycloalkyl-piperidines as modulators of chemokine receptor activity BRISTOL-MYERS SQUIBB PHARMA COMPANY 2003-02-13 US disclosed
WO-2002002525-A2 N-UREIDOHETEROCYCLOAKLYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2002-01-10 WO disclosed
EP-0423873-A2 Process for making improved citrus aqueous essence THE PROCTER & GAMBLE COMPANY (US) 1991-04-24 EP disclosed
US-4970085-A FLAVORS THE PROCTER & GAMBLE COMPANY (US) 1990-11-13 US disclosed
US-4929754-A CARDIOVASCULAR DISORDERS, ANTICOAGULANTS, ANTITUMOR AGENTS DR. KARL THOMAE GMBH (DE) 1990-05-29 US disclosed
US-4820705-A ANTITUMOR, CARDIOVASCULR DISORDERS DR. KARL THOMAE GMBH (DE) 1989-04-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058961-A1 N-ureidoheterocycloalkyl-piperidines as modulators of chemokine receptor activity CCR3, CCR1, ACKR3 CA2 1487/4885CA1 3245/4885CPB2 1612/4885
US-20030032654-A1 N-ureidoheterocycloalkyl-piperidines as modulators of chemokine receptor activity CCR3, CCR1, ACKR3 CA2 1487/4885CA1 3245/4885CPB2 1612/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.